Stryker (SYK) said Monday its OptaBlate basivertebral nerve ablation system received 510(k) clearance from the US Food and Drug Administration.
OptaBlate is used in a minimally invasive procedure to provide relief from vertebrogenic low back pain, the company said.
Stryker said the system, which expands its advanced pain therapy portfolio, combines its competencies in radiofrequency ablation and vertebral access.
Price: 393.34, Change: -0.88, Percent Change: -0.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.